ProofPilot has acquired Lokavant for an undisclosed amount. This corporate acquisition sees ProofPilot taking ownership of Lokavant, a clinical intelligence company known for its data-driven analytics platform that enhances trial execution. Lokavant's technology helps study teams aggregate and integrate real-time data from various trial sources, applying advanced analytics to manage and monitor studies proactively.
Lokavant's platform is designed to surface insights and drive efficiencies across clinical operations, including risk-based monitoring, operational study health tracking, trial planning and benchmarking, and medical monitoring. Its "Spectrum" product specifically utilizes Generative AI, Machine Learning, and Causal AI, built on proprietary data from over 500,000 trials, to provide adaptive, reliable forecasts, significantly reducing manual effort and uncertainty in clinical trial planning and execution.
The acquisition is a strategic move aimed at integrating Lokavant’s sophisticated clinical intelligence capabilities into ProofPilot’s operations. By bringing Lokavant’s AI-powered forecasting and real-time data insights under its umbrella, ProofPilot is positioned to offer a more robust and comprehensive suite of tools for managing clinical trials. The synergy is expected to enhance overall trial performance, streamline decision-making, and improve the predictability and success rates of research initiatives for a broader client base. This move is about expanding ProofPilot's technological assets, not about a funding round for either entity.
The combined entity will leverage Lokavant's deep analytical capabilities and extensive trial data expertise to further innovate in the clinical research landscape. This integration is anticipated to empower study teams with greater foresight and control, ultimately accelerating the development of new therapies. The acquisition underscores a commitment to advancing clinical trial methodologies through integrated technological solutions.